NR1H4 and primary biliary cholangitis: In the 2016, FDA approved the use of obethicholic acid (OCA) -- a transcriptional modifier of bile formation and a strong activator of the bile acid sensor FXR -- as a second therapy for PBC patients in combination with URSO or in those who are unresponsive to UDCA [76,77].